Literature DB >> 1337893

Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

R Snoeck1, G Andrei, D Schols, J Balzarini, E De Clercq.   

Abstract

The effects of different antiviral drug combinations on the replication of various human cytomegalovirus (CMV) strains in human embryonic lung (HEL) fibroblasts were evaluated. HPMPC combined with either ganciclovir, foscarnet or acyclovir showed additive to synergistic inhibition of CMV replication. Combinations of zidovudine with HPMPC, ganciclovir, foscarnet or acyclovir also resulted in additive to synergistic inhibition of CMV replication. Synergism tended to be higher for the clinical CMV isolates than for the reference strains AD-169 and Davis. Suppression of CMV replication was obtained at lower drug concentrations when the drugs were combined than when the drugs were used alone. At the highest drug concentrations used in the antiviral activity experiments, neither drug alone nor its combination suppressed host cell growth. If higher drug concentrations were used, zidovudine increased the inhibitory effects of ganciclovir, acyclovir and foscarnet but not of HPMPC, on cell proliferation. Use of combinations in the therapy of CMV infections may be considered to enhance drug efficacy, to reduce toxicity and, possibly, to diminish the risk of emergence of drug-resistant virus strains.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1337893     DOI: 10.1007/bf01961133

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  50 in total

1.  Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.

Authors:  J D Meyers; E C Reed; D H Shepp; M Thornquist; P S Dandliker; C A Vicary; N Flournoy; L E Kirk; J H Kersey; E D Thomas
Journal:  N Engl J Med       Date:  1988-01-14       Impact factor: 91.245

Review 2.  Treatment of CMV infections and disease in transplantation.

Authors:  G M Schmidt
Journal:  Transplant Proc       Date:  1991-06       Impact factor: 1.066

3.  Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient.

Authors:  K K Knox; W R Drobyski; D R Carrigan
Journal:  Lancet       Date:  1991-05-25       Impact factor: 79.321

4.  Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.

Authors:  O Ringdén; B Lönnqvist; T Paulin; J Ahlmén; G Klintmalm; B Wahren; J O Lernestedt
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

5.  Risk factors for cytomegalovirus infection after human marrow transplantation.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

6.  Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men.

Authors:  H Masur; H C Lane; A Palestine; P D Smith; J Manischewitz; G Stevens; L Fujikawa; A M Macher; R Nussenblatt; B Baird
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

7.  Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).

Authors:  J Neyts; R Snoeck; D Schols; J Balzarini; E De Clercq
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

8.  Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.

Authors:  J F Manischewitz; G V Quinnan; H C Lane; A E Wittek
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

9.  Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.

Authors:  G Klintmalm; B Lönnqvist; B Oberg; G Gahrton; J O Lernestedt; G Lundgren; O Ringdén; K H Robert; B Wahren; C G Groth
Journal:  Scand J Infect Dis       Date:  1985

10.  Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines.

Authors:  E De Clercq; T Sakuma; M Baba; R Pauwels; J Balzarini; I Rosenberg; A Holý
Journal:  Antiviral Res       Date:  1987-12       Impact factor: 5.970

View more
  9 in total

1.  Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy.

Authors:  Stuart T Hamilton; Manfred Marschall; William D Rawlinson
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  Antiviral properties of a series of 1,6-naphthyridine and 7, 8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus.

Authors:  J Bedard; S May; L L'Heureux; T Stamminger; A Copsey; J Drach; J Huffman; L Chan; H Jin; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 3.  Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 4.  Cidofovir.

Authors:  A P Lea; H M Bryson
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 5.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

6.  Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT-lipid-PFA on human herpesvirus-6B infected cells.

Authors:  Karen Yao; Christel Hoest; Farzin Rashti; Timm C Schott; Steven Jacobson
Journal:  J Clin Virol       Date:  2009-06-12       Impact factor: 3.168

Review 7.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 8.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 9.  Therapeutic Drug Monitoring of Ganciclovir: Where Are We?

Authors:  Anne-Grete Märtson; Angela E Edwina; Hannah Yejin Kim; Marjolein Knoester; Daan J Touw; Marieke G G Sturkenboom; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.